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Background-—A single NT-proBNP (N-terminal pro-B-type natriuretic peptide) measurement is a strong prognostic factor in adult
congenital heart disease. This study investigates NT-proBNP proﬁles within patients with adult congenital heart disease and relates
these to cardiovascular events.
Methods and Results-—In this prospective cohort, 602 patients with adult congenital heart disease were enrolled at the outpatient
clinic (years 2011–2013). NT-proBNP was measured at study inclusion in 595 patients (median age 33 [IQR 25–41] years, 58%
male, 90% NYHA I) and at subsequent annual visits. The primary end point was deﬁned as death, heart failure, hospitalization,
arrhythmia, thromboembolic event, or cardiac intervention; the secondary end point as death or heart failure. Repeated
measurements were analyzed using linear mixed models and joint models. During a median follow-up of 4.4 [IQR 3.8–4.8] years, a
total of 2424 repeated measurements were collected. Average NT-proBNP increase was 2.9 pmol/L the year before the primary
end point (n=199, 34%) and 18.2 pmol/L before the secondary end point (n=58, 10%), compared with 0.3 pmol/L in patients who
remained end point-free (P-value for difference in slope 0.006 and <0.001, respectively). In patients with elevated baseline NT-
proBNP (>14 pmol/L, n=315, 53%), repeated measurements were associated with the primary end point (HR per 2-fold higher
value 2.08; 95% CI 1.31–3.87; P<0.001) and secondary end point (HR 2.47; 95% CI 1.13–5.70; P=0.017), when adjusted for the
baseline measurement.
Conclusions-—NT-proBNP increased before the occurrence of events, especially in patients who died or developed heart failure.
Serial NT-proBNP measurements could be of additional prognostic value in the annual follow-up of patients with adult congenitive
heart disease with an elevated NT-proBNP. ( J Am Heart Assoc. 2018;7:e008349. DOI: 10.1161/JAHA.117.008349.)
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A congenital heart defect is the most prevalent congenitalanomaly, with an occurrence of 9 per 1000 live births.1
Because of the success of pediatric cardiology and cardio-
thoracic surgery, the population of patients with adult
congenital heart disease (ACHD) is rapidly growing. Currently
around 2.3 million patients with ACHD are estimated to be
alive in Europe, already outnumbering children with congenital
heart disease.2 Although survival has improved, residual
lesions may cause progressive exercise intolerance and late
complications such as arrhythmia, heart failure and sudden
death.3,4 This expanding demographic phenomenon is causing
serious issues about the optimal management of patients with
ACHD. Accurate biomarkers that enable risk stratiﬁcation and
monitoring of disease progression are therefore clearly
needed.
Natriuretic peptides are ﬁrmly established diagnostic and
prognostic tools in a variety of cardiovascular conditions, such
as heart failure and coronary heart disease.5,6 Previous
studies have shown that NT-proBNP (N-terminal pro-B-type
natriuretic peptide) is also a strong independent prognostic
factor in patients with ACHD.7–9 However, NT-proBNP is
known to have a considerable intra-individual biological
variability10 and progression of disease may lead to substan-
tial changes in the NT-proBNP level over time.11–14 Repeated
NT-proBNP measurements could therefore provide additional
prognostic information. The aim of this study was to
investigate the temporal evolution of NT-proBNP within
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individual patients and to relate this to cardiovascular events
in a prospective cohort study of patients with ACHD.
Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure upon reasonable request.
Study Design and Population
This prospective cohort study was conducted at the outpa-
tient clinic of a tertiary care center between April 2011 and
April 2013, that is responsible for the clinical care of all
patients with ACHD in the South-West region of The
Netherlands. A total of 602 consecutive patients with a
moderate or complex type of congenital heart defect15 who
routinely visited the outpatient clinic were enrolled in the
study cohort. Exclusion criteria were: aged <18 years,
pregnancy, mild cardiac lesion (isolated atrial or ventricular
septal defect), not capable of understanding and signing
informed consent, or kidney failure (creatinine >200 lmol/L).
According to the study protocol, participants underwent
physical examination by a cardiologist, 12-lead
electrocardiography, echocardiography and venous blood
sampling at the day of study inclusion. During four subse-
quent years, all patients were structurally followed-up by
yearly visits to the ACHD outpatient clinic, including physical
examination by a cardiologist, 12-lead electrocardiography,
and venous blood sampling. During follow-up, patients were
treated in accordance with ESC guidelines.16 Presence of
pulmonary hypertension was deﬁned as a right ventricular
systolic pressure of >40 mm Hg, as measured by the
tricuspid valve regurgitation maximal velocity (in patients
with a systemic left ventricle) or mitral valve regurgitation
maximal velocity (in patients with a systemic right ventricle)
and the estimated right atrial pressure, in accordance with the
guidelines.17 In patients with pulmonary stenosis we sub-
tracted the gradient across the pulmonary valve from the right
ventricular systolic pressure.18 The study protocol was
approved by the Erasmus MC medical ethics committee
and all participants provided written informed consent.
Other details of the study protocol have been described
previously.9,19
N-terminal pro-B-type natriuretic peptide
NT-proBNP was measured at inclusion and at the scheduled
yearly follow-up visits. Therefore, a maximum of ﬁve subse-
quent measurements per patient were collected. NT-proBNP
measurements were not part of standard clinical care at the
time this study was conducted. All measurements were
performed for research purposes only, and decisions on
patient management were made independently of any NT-
proBNP level. NT-proBNP was directly measured in fresh
serum samples at the clinical chemistry laboratory of the
Erasmus MC, using a commercial electrochemiluminescence
immunoassay (Roche Diagnostics, Rotkreuz, Switzerland). The
limit of detection was 0.6 pmol/L, and all values below the
limit of detection were reported as <0.6 pmol/L. Elevated NT-
proBNP was deﬁned as >14 pmol/L (>125 pg/mL), based
on the recommended low cut-off for the diagnosis of heart
failure in patients presenting with non-acute symptoms.20
Deﬁnition and Assessment of Events
The primary end point was deﬁned before the collection of
data as a composite of the following adverse (cardiovascular)
events: all-cause mortality, heart failure (requiring initiation or
change in heart failure medication, or requiring hospital
admission), hospitalization for cardiac reasons (including
heart failure, arrhythmia, thromboembolic event, cardiac
intervention, endocarditis, or other cardiac reasons requiring
admission 24 hours or longer), arrhythmia (symptomatic and
recorded, or requiring treatment), thromboembolic event
(ischemic cerebrovascular accident, pulmonary embolism or
Clinical Perspective
What Is New?
• NT-proBNP (N-terminal pro-B-type natriuretic peptide) is
associated with the risk of death or heart failure in patients
with adult congenital heart disease (ACHD).
• ACHD patients without cardiovascular events during 5-year
follow-up had stable and low NT-proBNP levels.
• NT-proBNP levels generally increased before the occurrence
of an adverse event in patients with ACHD, especially before
death or heart failure.
• Repeated NT-proBNP measurements were useful to improve
prognostication in patients with elevated (>14 pmol/L)
baseline values, since higher values, as well as (large)
variations were associated with an increased risk of adverse
cardiovascular events.
What Are the Clinical Implications?
• ACHD patients with low NT-proBNP concentrations
(<14 pmol/L) have a favorable prognosis, and serial mea-
surements will therefore be of limited additional value.
• ACHD patients with elevated NT-proBNP concentrations
(>14 pmol/L) have an increased risk of death or heart
failure.
• ACHD patients with elevated NT-proBNP concentrations
that have additional increments over time represent a
population that should receive close follow-up.
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myocardial infarction), or any cardiac intervention (surgical or
percutaneous). The secondary composite end point was
deﬁned as a composite of all-cause mortality or heart failure.
Patients were prospectively and systematically followed for
fatal and non-fatal events by a yearly clinical evaluation at our
institution according the study protocol until August 1, 2016.
We retrieved information from electronic patient charts and
also checked the survival status of patients in the Municipal
Population Register. Suspect end point events were adjudi-
cated by two experienced investigators (V.J.M.B. and J.W.R.-
H.) without knowledge of NT-proBNP levels.
Statistical Analysis
Variables are presented as meanstandard deviation or
median [interquartile range (IQR)], depending on the distribu-
tion of data. NT-proBNP had a skewed distribution and was
therefore log2 transformed for further analysis.
We adjudicated each component of the primary end point
(death, heart failure, hospitalization for cardiac reasons,
arrhythmia, thromboembolic event, and cardiac intervention)
separately. In other words, patients were followed until the
occurrence of the speciﬁc end point of interest and were not
censored at another end point type. This was important
because patients frequently experienced multiple event types
simultaneously or subsequently. For patients with multiple
events, event-free survival was deﬁned as the time from
enrollment to the occurrence of the ﬁrst event. Patients
without any cardiovascular event were censored at the end of
the follow-up duration. Cox proportional hazards regression
was performed to identify associations between baseline NT-
proBNP and the study end points. We conducted multivariable
analyses with adjustment for baseline age (years), sex,
congenital diagnosis (moderate versus complex), NYHA class
(I versus II–III), cardiac medication use (angiotensin-convert-
ing-enzyme inhibitors, angiotensin II receptor blockers, ß-
blockers, diuretics, calcium blockers, or anti-arrhythmic
drugs), loss of sinus rhythm, systemic ventricular function
(normal, mildly, moderately, or severely impaired), body mass
index (kg/m2), saturation <90%, ≥1 re-intervention after initial
corrective surgery, and estimated glomerular ﬁltration range
(eGFR; mL/min, log2-transformed). Data on covariates were
99.3% complete; we used imputation of the mean to account
for missing values.
We developed linear mixed-effects (LME) models to
describe the temporal NT-proBNP evolution, while accounting
for the correlation between subsequent NT-proBNP measure-
ments within individuals. In patients with study end points,
only NT-proBNP measurements before the study end point
were used. The model building and selection strategy for NT-
proBNP is further detailed in Data S1 and Table S1. We
developed models with adjustment for the full set of
covariates that were used in the Cox models. The proportion
of within-subject variation was calculated as the residual
variance of the LME model divided by the total variance. To
illustrate the average NT-proBNP evolution in patients with and
without events, an interaction term in the ﬁxed part of the
model was used to allow different slopes in patients with and
without events. We additionally developed LME models with
time point zero denoted as the moment at which patients
experienced an event, or when they were censored because of
reaching the end of the follow-up duration without experiencing
an event. Repeated NT-proBNPmeasurementswere denoted as
years before this moment (ie, on a negative timescale). These
models were used to calculate the increase in NT-proBNP in the
year before an event. To provide additional insight in the NT-
proBNP dynamics over time, we expressed the association
between baseline and follow-up NT-proBNP values by the
Spearman rank correlation coefﬁcient. In addition, we calcu-
lated quartiles of the change in NT-proBNP concentration in the
ﬁrst year (D year 1–year 0) and related this to baseline patient
characteristics and study end points. Hence, a positive value
indicates an increase in NT-proBNP in the ﬁrst year, and a
negative value indicates a decrease.
We used joint modeling (JM) to investigate the association
between the individual NT-proBNP evolutions over time and
the occurrence of study end points.21 JM combines the LME
model estimating the NT-proBNP level of an individual patient
at time t, with a Cox model to relate that estimated value with
the incidence of study end points after time t. Results are
presented as hazard ratios (HR) with 95% conﬁdence intervals
(CI) for a 2-fold higher value of the NT-proBNP level at any
time t between 0 and 4 years follow-up. HRs were adjusted
for the baseline NT-proBNP level by including baseline NT-
proBNP as a separate variable in the Cox model. In addition,
we constructed multivariate LME models including both serial
NT-proBNP and serial eGFR measurements, which were used
in a multivariate joint model to investigate the additive value
of serial NT-proBNP measurements on top of serial eGFR
measurements.
We repeated the JM analyses when stratiﬁed for normal
versus elevated NT-proBNP level at baseline, and stratiﬁed for
the absence or presence of pulmonary hypertension. In
addition, multiple explorative sub analyses were performed to
check the robustness of speciﬁc assumptions with regard to
end point deﬁnitions. Because a linear random slopes term
did not signiﬁcantly improve the ﬁt of the model, we only used
random intercepts and therefore did not calculate HRs for the
slope. Finally, although the present study was not speciﬁcally
designed to investigate NT-proBNP proﬁles in patients with a
cardiac intervention, we performed explorative post-hoc
analyses to evaluate whether we could detect a decrease in
NT-proBNP levels after a surgical or percutaneous valve
intervention among individual patients.
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We used IBM SPSS Statistics for Windows, version 21.0
(IBM Corp, Armonk, NY), and the nlme and JMBayes packages
in R statistical software, version 3.3.1 (available at: https://
www.r-project.org).22 Two-sided P-values <0.05 were consid-
ered statistically signiﬁcant.
Results
Patient Characteristics
A total of 595 patients underwent NT-proBNP measurement at
study inclusion. The median age was 33 [IQR 25–41] years
and 346 (58%) were male. Surgical repair of the congenital
defect before study entry was performed in 540 patients
(91%) at a median age of 3.7 [IQR 0.8–11.9] years), and 534
patients (90%) were in NYHA functional class I. The underlying
congenital diagnoses were congenital aortic stenosis (n=137),
aortic coarctation (n=109), repaired tetralogy of Fallot
(including pulmonary atresia with ventricular septal defect,
n=177), transposition of the great arteries (TGA) corrected by
atrial switch operation (Mustard, n=65), TGA corrected by
arterial switch operation (n=24), congenitally corrected TGA
(n=20), complex TGA with ventricular septal defect or double-
outlet right ventricle corrected with a Rastelli type repair
(n=11), functionally univentricular heart (n=43), and pul-
monary arterial hypertension after a (corrected) atrial or
ventricular septal defect (n=9). The majority of patients were
in sinus rhythm (n=514, 87%). Systemic ventricular function
was graded as normal (n=298, 50%), mildly impaired (n=210,
35%), moderately impaired (n=69, 12%), or severely impaired
(n=18, 3%). Right ventricular systolic pressure was available in
420 patients (71%), of whom 33 patients (7.9%) had
pulmonary hypertension. A ﬂowchart of the patient selection
and detailed clinical, electrocardiographic and echocardio-
graphic characteristics of the study cohort, also expressed
per baseline NT-proBNP quartile, have been previously
reported.9
Cardiovascular Events
Patients were followed-up during a median of 4.4 [IQR 3.8–
4.8] years. Survival status according to the Municipal
Population Register and detailed follow-up data about non-
fatal events were available in 590 patients (99.2%). The
primary end point occurred in 199 patients (34%) and the
secondary end point in 58 patients (10%). In total, 16 patients
died. Causes of death were: end-stage heart failure (n=8);
cardiac arrest (n=4); sudden death, presumed cardiac (n=3);
other (n=1). Other components of the primary end point were
heart failure (n=52), hospitalization for cardiac reasons
(n=151), arrhythmia (n=110), thromboembolic event (n=25),
and cardiac intervention (n=113).
Prognostic Value of Baseline NT-proBNP
Baseline NT-proBNP was signiﬁcantly associated with the
primary end point (crude HR per 2-fold higher value 1.55
[95% CI 1.43–1.68], P<0.001) and with the secondary end
point (crude HR per 2-fold higher value 2.30 [95% CI 1.97–
2.68], P<0.001). The Kaplan-Meier estimate of primary end
point-free survival at 4 years of follow-up was 84.1% in
patients with normal baseline NT-proBNP (<14 pmol/L) and
55.1% in patients with elevated baseline NT-proBNP.
Secondary end point-free survival at 4 years of follow-up
was 99.3% in patients with normal baseline NT-proBNP
(<14 pmol/L) and 83.2% in patients with elevated baseline
NT-proBNP. After complete adjustment for all covariates, the
strength of the association was slightly attenuated but
remained signiﬁcant for both the primary end point (adjusted
HR per 2-fold higher value 1.39 [95% CI 1.23–1.57], P<0.001)
and the secondary end point (adjusted HR per 2-fold higher
value 1.80 [95% CI 1.42–2.28], P<0.001). The prognostic
value of baseline NT-proBNP in this cohort has been
previously published (using standardized HRs).9 Of note,
baseline eGFR measurements were not predictive of the
primary and secondary end point in these multivariable
models (adjusted HR per 2-fold higher value 1.00 [95% CI
0.58–1.72], P=0.993 and 2.49 [95% CI 0.78–7.89], P=0.123,
respectively).
Temporal NT-proBNP Evolution
During the follow-up, a median of 4 yearly repeated NT-
proBNP measurements were collected per patient, resulting in
a total of 2424 measurements. For the analysis of the primary
end point 2009 measurements were available, and for the
analysis of the secondary end point 2319 measurements were
available. Figures 1 and 2 describe the average NT-proBNP
proﬁles in patients with and without the primary and
secondary end point, respectively. Individual NT-proBNP
proﬁles are depicted in Figures S1 and S2. Of the total
variation in the NT-proBNP level, 89% was attributable to
variation between subjects and 11% to variation within
subjects.
The average baseline NT-proBNP (intercept) in patients
who reached the primary end point was 30.6 (95% CI 25.8–
36.2) pmol/L, compared with 10.6 (95% CI 9.6–
11.8) pmol/L in patients who remained event-free during
the follow-up (P-value <0.001). The average NT-proBNP
increase in the last year before the primary end point was
2.9 pmol/L, compared with 0.3 pmol/L in patients with-
out the end point (P-value for difference in slope 0.006).
In patients who reached the secondary end point, the
average baseline NT-proBNP was 73.7 (95% CI 56.1–96.8)
pmol/L, compared with 12.9 (11.7–14.1) pmol/L in patients
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without the end point (P-value <0.001). The average NT-
proBNP increase in the last year before the secondary end
point was 18.2 pmol/L, compared with 0.3 pmol/L in
patients without the secondary end point (P-value for
difference in slope <0.001).
The Spearman correlation coefﬁcient of the baseline NT-
proBNP measurement with years 1, 2, and 3, respectively,
was 0.84, 0.85, and 0.86 in subjects without any event;
0.85, 0.82, and 0.87 in subjects with the primary end point;
and 0.88, 0.75, and 0.79 in subjects with the secondary
end point (all P<0.001). In Table 1, quartiles of the change
in NT-proBNP concentration in the ﬁrst year are related to
baseline patient characteristics. Patients in the highest
quartile (ie, with the largest increase in NT-proBNP level
within the ﬁrst year) were signiﬁcantly older, were more
likely to be female, had a higher age at initial surgical
repair, more frequently used cardiac medication, were in a
higher NYHA class and had a worse systemic ventricular
function. Of note, in this type of statistical analysis only a
subset of the data is used and regression to the mean
partly explains the differences in NT-proBNP levels between
patient subgroups. The exact results should therefore be
carefully interpreted.
Prognostic Value of Repeated Measurements
The HRs of the repeatedly measured NT-proBNP value indicate
the risk of the primary and secondary end point for a 2-fold
higher value of NT-proBNP, measured at any time t between 0
and 4 years of follow-up (Table 2). These HRs were conse-
quently higher than the HRs of the single baseline NT-proBNP
value, calculated using Cox regression (as reported in the text
above). This indicates that the repeated NT-proBNP measure-
ments that were taken during the follow-up were more
predictive of the primary and secondary end point than the
single baseline value.
The NT-proBNP level at any point in time during the follow-
up was even stronger associated with the study end points
when adjustment was performed for the baseline NT-proBNP
level. That is when two patients with the same NT-proBNP
level at baseline were compared, higher values during follow-
up were strongly predictive of study end points (Table 2).
The stratiﬁed analysis reported in Table 3 shows that the
repeated measurements seem to carry additional prognostic
value on top of the baseline value in both patients with a
normal NT-proBNP level and patients with an elevated NT-
proBNP level at baseline. However, this association is
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Figure 1. Average NT-proBNP (N-terminal pro-B-type natriuretic peptide) evolution in patients with and without the primary end point. NT-
proBNP measurements after the event were deleted, therefore a total of 2009 measurements that occurred before the primary end point were
used in this analysis. A, time point zero is denoted as the date of study inclusion (and ﬁrst NT-proBNP measurement). B, time point zero is
denoted as the moment at which patients either experienced an event, or when they were censored because of reaching the end of the follow-up
duration without experiencing an event. We displayed all repeated NT-proBNP measurements as years before this moment (ie, on a negative
timescale).
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probably underpowered in the group of patients with a normal
baseline NT-proBNP, since the event rates of the primary end
point and especially the secondary end point (which may be
considered as most clinically relevant in this matter) were
very low in these patients. A stratiﬁed analysis based on the
absence (n=387) or presence (n=33) of pulmonary hyperten-
sion showed repeated NT-proBNP measurements were asso-
ciated with the primary and secondary end point in both
groups (P<0.001 for all analyses). Additional explorative sub
analyses excluding cardiac interventions from the primary end
point, and separately analyzing heart failure requiring hospi-
talization versus heart failure requiring medication change or
initiation did not yield different conclusions.
Finally, in Figure 3, the association between the change in
NT-proBNP level in the ﬁrst year (D year 1–year 0) and the
study end points is depicted.
NT-proBNP Response after Cardiac Intervention
Of the 113 patients with a cardiac intervention, 41 patients
underwent a surgical intervention (valvular replacement,
n=35; valvular repair, n=4; aortic surgery, n=1; and defect
closure, n=1) and 72 patients underwent a percutaneous
intervention (ablation, n=21; pacemaker or ICD implantation,
n=20; valve replacement, n=16; coronary intervention, n=5;
defect closure, n=4; valvular balloon dilatation, n=4; aortic
stenting, n=2). To explore whether interventions with a
volume or pressure load reduction on the heart were followed
by a decrease in NT-proBNP level among individual patients,
we plotted the NT-proBNP proﬁles of all patients with a
surgical valve intervention (valve replacement or valve repair)
and with a percutaneous valve intervention (valve replacement
or balloon dilatation) in Figure S3. Within individual patients,
large reductions in the NT-proBNP level were observed after the
valvular intervention, especially in the surgical valve interven-
tion group. Other exploratory analyses are shown in Figure S4
(NT-proBNP proﬁles in patients with elective versus non-
elective cardiac interventions) and in Figure S5 (NT-proBNP
proﬁles in patients with sudden cardiac death).
Discussion
In this study, we describe yearly repeated NT-proBNP mea-
surements in adult patients with congenital heart disease for
the ﬁrst time. Baseline NT-proBNP levels in patients with an
event were markedly higher, especially in patients who
developed heart failure or died. In addition, NT-proBNP levels
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Figure 2. Average NT-proBNP (N-terminal pro-B-type natriuretic peptide) evolution in patients with and without the secondary end point. NT-
proBNP measurements after the event were deleted, therefore a total of 2319 measurements that occurred before the secondary end point
were used in this analysis. A, time point zero is denoted as the date of study inclusion (and ﬁrst NT-proBNP measurement). B, time point zero is
denoted as the moment at which patients either experienced an event, or when they were censored because of reaching the end of the follow-up
duration without experiencing an event. We displayed all repeated NT-proBNP measurements as years before this moment (ie, on a negative
timescale).
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generally increased before the occurrence of an event, whereas
patients without any cardiovascular event exhibited stable and
low NT-proBNP levels. Consequently, when 2 patients with the
same NT-proBNP level at baseline were compared, higher
values measured during the follow-up were strongly indicative
of events. Repeated measurements were especially of value in
patients with an elevated NT-proBNP at baseline.
Repeated Biomarker Measurements
Repeated NT-proBNP sampling allows the quantiﬁcation of a
change in levels over time. Although, in general, NT-proBNP
concentrations were relatively stable over time and the
average increase in patients with the primary end point was
modest, the occurrence of death or heart failure was
Table 1. Association Between Baseline Patient Characteristics and Quartiles of the Difference in NT-proBNP (pmol/L) Between
Year 1 and Year 0
No Measurement
At Year 1 (n=33)
Change in NT-proBNP (pmol/L) Calculated by Year 1 to Year 0
P Value (n=562)
Q1 (Δ <4.1
pmol/L, n=140)
Q2 (Δ 4.1 to 0.0
pmol/L, n=144)
Q3 (Δ 0.0–5.1
pmol/L, n=138)
Q4 (Δ >5.1
pmol/L, n=140)
Clinical characteristics
Age, y 32.8 [25.7–43.4] 32.5 [25.5–41.4] 31.2 [24.1–39.5] 28.8 [22.2–37.6] 37.0 [28.7–45.2] <0.001
Sex, male n (%) 20 (61) 69 (49) 92 (64) 93 (67) 72 (51) 0.003
Surgical repair, n (%) 30 (91) 132 (94) 124 (86) 123 (89) 131 (94) 0.057
Age at surgical repair, y 1.7 [0.3–6.6] 3.6 [0.9–13.8] 3.4 [0.4–13.2] 2.9 [0.8–9.4] 6.5 [1.1–15.5] 0.017
Congenital diagnosis, n (%)* 20 (61) 83 (59) 66 (46) 72 (52) 84 (60) 0.054
Cardiac medication use, n (%) 9 (27) 59 (42) 38 (26) 36 (26) 70 (50) <0.001
Body mass index, kg/m2 24.25.4 24.94.5 24.94.6 24.24.2 24.94.0 0.423
Heart rate, beats/minute 7217 7313 7313 7313 7613 0.261
Systolic blood pressure, mm Hg 12212 12718 12816 12616 12516 0.531
O2 saturation <90%, n (%) 1 (3) 4 (3) 1 (1) 6 (4) 5 (4) 0.309
NYHA class, II to III n (%) 4 (12) 16 (11) 7 (5) 9 (7) 25 (18) 0.001
ECG
Sinus rhythm, n (%) 28 (85) 117 (84) 132 (92) 121 (88) 116 (83) 0.108
QRS duration, ms 111 [97–132] 115 [101–142] 109 [99–126] 112 [99–140] 118 [100–152] 0.069
Echocardiogram
LA volume, mL/m2† 20 [14–27] 22 [17–35] 20 [15–25] 20 [15–27] 23 [16–34] 0.009
LV end-diastolic volume, mL/m2† 5713 6720 6117 6519 6220 0.125
LV end-systolic volume, mL/m2† 247 3012 2710 2911 3018 0.421
LV ejection fraction, %† 586 567 567 577 5411 0.237
RV fractional area change, % 3512 3811 3912 4110 3611 0.019
Systemic ventricular function, n (%) 0.001
Normal 20 (61) 67 (48) 74 (51) 86 (62) 51 (36)
Mildly impaired 10 (30) 45 (32) 53 (37) 44 (32) 58 (42)
Moderately impaired 3 (9) 21 (15) 13 (9) 7 (5) 25 (18)
Severely impaired 0 (0) 7 (5) 4 (3) 1 (1) 6 (4)
Laboratory results
eGFR, mL/min 90 [89–90] 90 [81–90] 90 [83–90] 90 [84–90] 90 [79–90] 0.048
NT-proBNP, pmol/L (year 0) 14.4 [5.9–26.0] 32.5 [18.7–59.0] 8.9 [5.5–6.1] 7.3 [3.7–15.3] 24.2 [9.7–56.9] <0.001
Values are reported as n (%), meanSD or median [IQ1–IQ3]. Differences across quartiles of change are analyzed using the chi-square test for categorical data, One-Way ANOVA or Kruskal-
Wallis for continuous data (depending on the distribution). No trend tests were used, because not necessarily a linear relationship is assumed. eGFR indicates estimated glomerular
ﬁltration rate; LA, left atrial; LV, left ventricular; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular.
*Congenital diagnosis of aortic stenosis, aortic coarctation or arterial switch operation (0) vs tetralogy of Fallot, Rastelli, systemic RV, univentricular heart or pulmonary arterial
hypertension (1).
†Left-sided volumes were not measured in patients with a systemic right ventricle, functionally univentricular heart, pulmonary hypertension (n=137) or a poor acoustic window.
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preceded by a substantial change in NT-proBNP level. The
annual increase before the occurrence of death or heart
failure was 25% of the baseline value, and may therefore be
considered clinically meaningful. This is in line with previous
studies in patients with chronic heart failure, showing that
changes in NT-proBNP level over time are associated with an
individual’s prognosis.11–14
Using all repeated NT-proBNP measurements in the JM
yielded a higher HR compared with using only the baseline
value in the Cox model. This may be explained by the fact that
the JM incorporates all NT-proBNP values that were subse-
quently taken during the follow-up, and were thus also
measured closer to the occurrence of adverse events. A
measurement close to the occurrence of an adverse event
could better reﬂect an individual’s disease status at that time.
Accordingly, in a study on chronic heart failure patients by
Masson et al, a single NT-proBNP value at 4 months of follow-
up was found to have a greater prognostic accuracy than
baseline NT-proBNP.11
Although the exact results must be interpreted with great
caution because only a subset of the data is used and
regression to the mean can play a role, the conventional
statistical analyses (Figure 3) conﬁrm our main analysis, and
show that the 25% of patients with the largest increase in NT-
proBNP during the ﬁrst year (>5.1 pmol/L) were at highest
risk of the primary and secondary study end point. Interest-
ingly, the 25% of patients with the largest decrease in NT-
proBNP (<4.1 pmol/L) also had a high risk of the study end
points. These data suggest that variations in NT-proBNP level
are associated with an increased risk of adverse events, and
that the observed direction of change is dependent on the
coincidental moment on which the biomarker is measured
(note that our patients were clinically stable). Furthermore,
patients with more variation in their NT-proBNP level also
appear to have higher baseline NT-proBNP levels (Table 1).
Comparable ﬁndings have been reported by Masson et al in
patients with chronic heart failure, showing that patients with
the largest absolute change in NT-proBNP level within the ﬁrst
4 months had a higher all-cause mortality risk than patients
with a relative stable level.11 Of note, the strength of
evaluating >2 measurements per patient with LME models
(as applied in this study), is that it becomes possible to adjust
for this variation and to quantify gradual increases in the
average NT-proBNP level over time.
Regression to the Mean
An extreme measurement has the tendency to become less
extreme when it is measured again, because of the intra-
patient ﬂuctuations around a true mean. This statistical
phenomenon is called regression to the mean, and especially
occurs when an analyzed variable has a substantial within-
subject variability over time.23–25 NT-proBNP is known to have
a substantial intra-individual biological variation.10 Regression
to the mean is therefore an important concept to consider
when serial measurements are analyzed, and differences
between two subsequent measurements cannot be directly
translated into a true increase or decrease. Multiple (>2)
measurements provide more accurate estimations of an
individual’s true average NT-proBNP level, and better allow
analysis of biomarker evolution over time.
Most of the studies that have evaluated repeated NT-
proBNP measurements to date, have assessed the difference
between two subsequent NT-proBNP measurements and
related relative, absolute and/or categorical changes to
adverse events.11–14 This is the ﬁrst time that multiple
Table 2. Hazard Ratios Per 2-Fold Higher Value of the
Biomarker, Calculated Using a Joint Model
HR (95% CI) P Value
Primary end point
Repeated NT-proBNP
measurements*
1.63 (1.49–1.76) <0.001
Adjusted for baseline
characteristics*,†
1.55 (1.35–1.79) <0.001
Additionally adjusted for
baseline NT-proBNP†,‡
2.05 (1.23–3.66) <0.001
Repeated NT-proBNP and eGFR measurements§
Repeated NT-proBNP
measurements
1.60 (1.50–1.71) <0.001
Repeated eGFR
measurements
0.88 (0.67–1.16) 0.266
Secondary end point
Repeated NT-proBNP
measurements*
2.46 (2.04–2.87) <0.001
Adjusted for baseline
characteristics*,†
2.10 (1.64–2.75) <0.001
Additionally adjusted for
baseline NT-proBNP†,‡
4.44 (1.50–13.7) <0.001
Repeated NT-proBNP and eGFR measurements§
Repeated NT-proBNP
measurements
2.51 (2.20–2.92) <0.001
Repeated eGFR measurements 1.30 (0.87–2.11) 0.166
CI indicates conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HR, hazard
ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*HR for a patient with a 2-fold higher NT-proBNP level than another patient at any point
in time during the follow-up.
†Adjusted for age (years), sex (0–1), congenital diagnosis (moderate vs complex), NYHA
class (I vs II–III), cardiac medication use (0–1), loss of sinus rhythm (0–1), systemic
ventricular function (0–3), body mass index (kg/m2), saturation <90%, ≥1 re-intervention
after initial corrective surgery, and eGFR (mL/min, log2-transformed).
‡HR for a patient with a 2-fold higher NT-proBNP level than another patient at any point
in time during the follow-up, when two patients with the same baseline NT-proBNP level
are compared.
§Analyzed using a multivariate joint model (including both repeated NT-proBNP and
repeated eGFR measurements).
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repeated NT-proBNP values are investigated, and that JM
techniques are applied. An important advantage of JM is that
the LME model part takes into account the random within-
subject variation (11% of the total variation in our study).
Because this allows adjustment for the inherent biological
variation and regression to the mean, this sophisticated
statistical technique produces more reliable estimates of the
true NT-proBNP proﬁle of individual patients.
Clinical Implications
Patients with an elevated NT-proBNP level at baseline are
clearly at higher risk of adverse cardiovascular events.9 In
these patients, it seems reasonable to regularly check the NT-
proBNP level by an annual measurement, because especially
the increase in the year before the occurrence of death or
heart failure was substantial (25%). Moreover, in this group
the repeated measurements were independently associated
with study end points when adjustment was performed for the
baseline NT-proBNP measurement. Patients with high NT-
proBNP levels seem to have more biological variation;
therefore, it could be important to perform multiple (>2)
measurements, to detect a gradual increase in the NT-proBNP
over time. Patients with a high NT-proBNP level and patients
with a substantial increase over time may require more
frequent follow-up visits or timely initiation or expansion of
Figure 3. Association of the change in NT-proBNP concentration in the ﬁrst year (D year 1–year 0) with the primary and secondary study end
point. Only a subset of the data could be used for this conventional type of analysis, because all measurements after year 1 were discarded, the
time-to-event was recalculated from year 1 onwards and patients with a study end point in the ﬁrst year were excluded. Hence, for the analysis
of the primary and secondary end points, 488 and 546 patients were available, respectively.
Table 3. Hazard Ratios Per 2-Fold Higher Value of NT-proBNP, Calculated Using a Joint Model: Stratiﬁed Analysis in Patients With
Baseline BNP <14 pmol/L (Normal) and >14 pmol/L (Elevated)
Baseline NT-proBNP <14 pmol/L (Normal, n=280) Baseline NT-proBNP >14 pmol/L (Elevated, n=315)
No. Cases Crude HR (95% CI) P Value No. Cases Crude HR (95% CI) P Value
Primary end point 50 149
Repeated NT-proBNP measurements* 1.61 (1.10–2.52) 0.011 1.65 (1.46–1.86) <0.001
Adjusted for baseline NT-proBNP† 2.03 (0.88–4.71) 0.098 2.08 (1.31–3.87) <0.001
Secondary end point 2 56
Repeated NT-proBNP measurements* 3.67 (0.41–63.2) 0.284 2.30 (1.89–2.86) <0.001
Adjusted for baseline NT-proBNP† 6.62 (0.10–1026) 0.435 2.47 (1.13–5.70) 0.017
CI indicates conﬁdence interval; HR, hazard ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*HR for a patient with a 2-fold higher NT-proBNP level than another patient at any point in time during the follow-up.
†HR for a patient with a 2-fold higher NT-proBNP level than another patient at any point in time during the follow-up, when two patients with the same baseline NT-proBNP level are
compared.
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heart failure medication. The optimal frequency of repeated
measurements cannot be determined from these data and
warrants future research.
In contrast, in patients with a normal NT-proBNP level at
baseline (<14 pmol/L, 47% of our study population) the NT-
proBNP concentration was relatively stable and the event
rates were much lower. Especially the risk of death and heart
failure was extremely low, which emphasizes the high
negative predictive value of NT-proBNP.9 Because of these
low event rates, no signiﬁcant additional value of repeated
measurements could be shown in this group. Our pragmatic
interpretation of these results is as follows: because the
absolute risk of events is low in this group, even an increased
relative risk for higher values during follow-up (which did not
reach statistical signiﬁcance in our study) would add limited
information. It therefore seems unnecessary to repeat NT-
proBNP measurements annually in these patients to obtain
additional prognostic information. The clinical implication of
not needing annual repeated measurements in patients with
normal NT-proBNP also includes a possible positive cost-
effect, because these measurements are relatively expensive.
It may be advisable to update information on NT-proBNP
levels at a lower frequency, for instance every 4 or 5 years. To
provide evidence for this, studies with a much longer follow-
up duration are needed.
Finally, NT-proBNP might be useful as a biomarker to detect
a response to successful interventions, because we observed
large NT-proBNP reductions among individual patients, espe-
cially after surgical valve interventions. Whether this could
actually improve the patient selection and timing for re-
intervention warrants future studies including more frequent
NT-proBNP measurements that are scheduled at pre-deﬁned
time points both before and after valvular interventions.
Study Limitations
Although we performed multivariable adjustment for multiple
covariates such as age, sex, congenital diagnosis, NYHA class,
cardiac medication use, rhythm, systemic ventricular function,
body mass index, saturation, re-intervention, and eGFR, this is
an observational study subject to residual confounding. For
instance, our cohort consisted of a relatively heterogeneous
group of multiple congenital diagnoses, and we could only
adjust for a dichotomized variable indicating a moderate (0) or
complex (1) type of congenital diagnosis. Other variables that
were not taken into account in this analysis may also play a
role in the prognostication of patients with ACHD. Of note,
patients with mild cardiac lesions such as isolated atrial or
ventricular septal defect were excluded in this study, because
the expected event rate in these patients is very low. This
should be considered when these results are compared with
other cohorts of patients with ACHD.
In this study, only repeated NT-proBNP and repeated eGFR
measurements were analyzed. However, also changes in other
biomarkers with less day-to-day variations or other patient
characteristics could play a role in the prognostication of
patients with ACHD. We did not take repeated 2-dimensional
echocardiographic measurements into account, because
these are known to have a relatively large measurement
error and we therefore did not consider these suitable for
accurate quantiﬁcation of serial changes.26 Other repeatedly
assessed clinical variables were not available. Ideally, updat-
ing multiple variables during each follow-up visit could lead to
more precise and individualized dynamic predictions.
Finally, we used composite end points in this study, and it
should be taken into account that the individual components
are not all of similar clinical importance to the patient.
Conclusions
A single measurement of NT-proBNP at any time during the
follow-up is of important prognostic value in patients with
ACHD who routinely visit the outpatient clinic. In patients with
a normal NT-proBNP level, it is not needed to annually repeat
NT-proBNP measurements to obtain additional prognostic
information. In patients with an elevated NT-proBNP level,
yearly repeated measurements were strongly predictive of
study end points and provided signiﬁcant prognostic informa-
tion beyond the baseline NT-proBNP level. In these patients,
serial measurements may therefore aid in the further
optimization of individual follow-up strategies, medical ther-
apies, and timing of re-interventions.
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Supplemental Methods  
 
Linear mixed-effects model building and selection.  
 
We used all NT-proBNP measurements that occurred prior to the primary endpoint (n=2009), with a 
median of 4 measurements per patient. We started with a LME with linear and quadratic time evolutions, 
a nonlinear effect of age using natural cubic splines with 3 degrees of freedom, the main effects of sex, 
diagnosis, NYHA class, medication use, rhythm, systemic ventricular function, BMI, saturation, re-
intervention and logeGFR, and the interactions of time with sex and diagnosis (Model 1). 
We first expanded the random-effects structure, while keeping the same fixed effects, in order to 
appropriately model the correlations in the repeated NT-proBNP measurements. We therefore included 
the linear random slopes term (Model 2) and tested whether this improved the fit of the model by using a 
likelihood ratio test, which was not the case (P=0.323). Therefore, we continued with a model with only 
random intercepts.  
 To define the fixed part of the model, we subsequently tested whether the interaction terms had 
an important contribution to the fit of the model. To this end, we refitted Model 1 under maximum 
likelihood (instead of the default restricted maximum likelihood) and then fitted another model without 
the interaction terms (Model 3). The results suggested that the effects of time do not differ between men 
and women, and between patients with a moderate or complex diagnosis (P=0.249). We continued by 
performing the omnibus test for all nonlinear terms in the model. We therefore fitted the model that 
excluded all nonlinear terms (Model 4) and compared this with Model 3 using the likelihood ratio test. 
This indicated that the nonlinear terms did not have a significant contribution to the model (P=0.096).  
Therefore, the final selected model for the log2 transformed serial NT-proBNP measurements was 
a random intercepts LME with a linear time evolution, and main effects of age (linear), sex, diagnosis, 
NYHA class, medication use, rhythm, systemic ventricular function, BMI, saturation, re-intervention and 
logeGFR. A schematic overview of the LME model building and selection is presented in Supplemental 
Table 1. This model was refitted with restricted maximum likelihood and further used for the estimation 
of the temporal NT-proBNP evolution. Of note, the joint models were estimated using a Bayesian 
framework.
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Table S1. Linear mixed-effects model building and selection.  
NT-proBNP 
model Fixed Random LRT 
Compared with 
(method) 
1 logBNP ~ (obstimeyr + I(obstimeyr^2)) * 
(sex + diagnosis) + ns(age,3) + NYHA + 
medication + rhythm + systfunc + BMI + 
saturation + reintervention + logeGFR 
~ 1 | id     
2 Equal to model 1 ~ obstimeyr | 
id 
P=0.323 Model 1 (REML) 
3 logBNP ~ (obstimeyr + I(obstimeyr^2)) + 
sex + diagnosis + ns(age,3) + NYHA + 
medication + rhythm + systfunc + BMI + 
saturation + reintervention + logeGFR 
~ 1 | id P=0.249 Model 1 (ML) 
4 logBNP ~ obstimeyr + sex + diagnosis + age 
+ NYHA + medication + rhythm + systfunc 
+ BMI + saturation + reintervention + 
logeGFR 
~ 1 | id P=0.096 Model 3 (ML) 
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Figure S1. Individual NT-proBNP profiles in patients without and with the primary endpoint. 
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Figure S2. Individual NT-proBNP profiles in patients without and with the secondary endpoint. 
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Figure S3. NT-proBNP profiles in patients with a surgical or percutaneous valve intervention (at time point 0). 
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Figure S4. NT-proBNP profiles in patients with elective versus non-elective cardiac interventions. 
 
Of the 113 cardiac interventions, 17 were non-elective (pacemaker or ICD implantation, n=10; surgical 
aortic valve replacement, n=4; percutaneous pulmonary valve dilatation, n=1; coronary intervention, n=1; 
ablation, n=1). No clear differences in the NT-proBNP profiles were observed, probably because the 
group of patients with a non-elective intervention was relatively small and heterogeneous.  
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Figure S5. NT-proBNP profiles in patients with sudden cardiac death. 
 
The 7 patients with sudden cardiac death had higher NT-proBNP levels at baseline that increased over 
time in all patients. Because of the low (expected) number of patients with sudden cardiac death, we did 
not aim to make predictions for this specific endpoint. 
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